A pilot study to investigate the efficacy and tolerability of lesion network guided transcranial electrical stimulation in outpatients with psychosis spectrum illness.
Lesion Network Mapping
Positive Symptoms
Transcranial Electrical Stimulation
Journal
Asian journal of psychiatry
ISSN: 1876-2026
Titre abrégé: Asian J Psychiatr
Pays: Netherlands
ID NLM: 101517820
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
26
07
2023
revised:
09
08
2023
accepted:
17
08
2023
pmc-release:
01
10
2024
medline:
9
10
2023
pubmed:
27
8
2023
entrez:
26
8
2023
Statut:
ppublish
Résumé
Transcranial electrical stimulation (tES) may improve psychosis symptoms, but few investigations have targeted brain regions causally linked to psychosis symptoms. We implemented a novel montage targeting the extrastriate visual cortex (eVC) previously identified by lesion network mapping in the manifestation of visual hallucinations. To determine if lesion network guided High Definition-tES (HD-tES) to the eVC is safe and efficacious in reducing symptoms related to psychosis. We conducted a single-blind crossover pilot study (NCT04870710) in patients with psychosis spectrum disorders. Participants first received HD-tDCS (direct current), followed by 4 weeks of wash out, then 2 Hz HD-tACS (alternating current). Participants received 5 days of daily (2×20 min) stimulation bilaterally to the eVC. Primary outcomes included the Positive and Negative Syndrome Scale (PANSS), biological motion task, and Event Related Potentials (ERP) from a steady state visual evoked potential (SSVEP) paradigm. Secondary outcomes included the Montgomery-Asperg Depression Rating Scale, Global Assessment of Functioning (GAF), velocity discrimination and visual working memory task, and emotional ERP. HD-tDCS improved PANSS general psychopathology in the short-term (d=0.47; p Lesion network guided HD-tES to the eVC is a safe, efficacious, and promising approach for reducing general psychopathology via changes in neuroplasticity. These results highlight the need for larger clinical trials implementing novel targeting methodologies for the treatments of psychosis.
Sections du résumé
BACKGROUND
BACKGROUND
Transcranial electrical stimulation (tES) may improve psychosis symptoms, but few investigations have targeted brain regions causally linked to psychosis symptoms. We implemented a novel montage targeting the extrastriate visual cortex (eVC) previously identified by lesion network mapping in the manifestation of visual hallucinations.
OBJECTIVE
OBJECTIVE
To determine if lesion network guided High Definition-tES (HD-tES) to the eVC is safe and efficacious in reducing symptoms related to psychosis.
METHODS
METHODS
We conducted a single-blind crossover pilot study (NCT04870710) in patients with psychosis spectrum disorders. Participants first received HD-tDCS (direct current), followed by 4 weeks of wash out, then 2 Hz HD-tACS (alternating current). Participants received 5 days of daily (2×20 min) stimulation bilaterally to the eVC. Primary outcomes included the Positive and Negative Syndrome Scale (PANSS), biological motion task, and Event Related Potentials (ERP) from a steady state visual evoked potential (SSVEP) paradigm. Secondary outcomes included the Montgomery-Asperg Depression Rating Scale, Global Assessment of Functioning (GAF), velocity discrimination and visual working memory task, and emotional ERP.
RESULTS
RESULTS
HD-tDCS improved PANSS general psychopathology in the short-term (d=0.47; p
CONCLUSION
CONCLUSIONS
Lesion network guided HD-tES to the eVC is a safe, efficacious, and promising approach for reducing general psychopathology via changes in neuroplasticity. These results highlight the need for larger clinical trials implementing novel targeting methodologies for the treatments of psychosis.
Identifiants
pubmed: 37633159
pii: S1876-2018(23)00306-4
doi: 10.1016/j.ajp.2023.103750
pmc: PMC10591953
mid: NIHMS1929437
pii:
doi:
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
103750Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002541
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors report no conflicts of interest.
Références
Am J Psychiatry. 2020 Apr 1;177(4):342-353
pubmed: 31838873
Neuroimage. 2013 Jul 1;74:266-75
pubmed: 23370061
Biol Psychiatry. 2022 Sep 1;92(5):396-406
pubmed: 35688762
Schizophr Bull. 2023 Feb 24;49(Supplement_1):S68-S81
pubmed: 36840543
Front Psychiatry. 2012 Oct 22;3:91
pubmed: 23097644
Int J Geriatr Psychiatry. 2008 Jul;23(7):712-8
pubmed: 18181237
Asian J Psychiatr. 2021 Dec;66:102887
pubmed: 34740126
Harv Rev Psychiatry. 2022 May-Jun 01;30(3):181-190
pubmed: 35576449
J Neural Transm (Vienna). 2016 Oct;123(10):1213-7
pubmed: 27194229
Exp Neurol. 1962 Jun;5:436-52
pubmed: 13882165
Expert Opin Drug Metab Toxicol. 2021 Oct;17(10):1211-1221
pubmed: 34461790
Proc Natl Acad Sci U S A. 2022 Oct 18;119(42):e2210412119
pubmed: 36191179
Psychopathology. 2007;40(6):418-23
pubmed: 17652954
Front Neurosci. 2017 Nov 22;11:641
pubmed: 29213226
Curr Biol. 2008 Dec 9;18(23):1839-43
pubmed: 19026538
Neuropsychiatr Dis Treat. 2020 Feb 21;16:519-534
pubmed: 32110026
Schizophr Res. 2019 Jun;208:196-201
pubmed: 30842029
Mol Psychiatry. 2021 Apr;26(4):1299-1309
pubmed: 31659272
Nat Rev Neurosci. 2003 Mar;4(3):219-29
pubmed: 12612634
Am J Psychiatry. 2018 Dec 1;175(12):1243-1254
pubmed: 30278791
Dialogues Clin Neurosci. 2004 Mar;6(1):61-70
pubmed: 22034144
Schizophr Bull. 2014 Jul;40 Suppl 4:S233-45
pubmed: 24936084
Schizophr Bull. 2019 Apr 25;45(3):522-530
pubmed: 30304518
Front Behav Neurosci. 2018 May 28;12:94
pubmed: 29892215
Med Eng Phys. 2020 Nov;85:63-74
pubmed: 33081965
Cereb Cortex. 2013 May;23(5):1108-17
pubmed: 22535908
Asian J Psychiatr. 2021 Feb;56:102542
pubmed: 33486461
JAMA Psychiatry. 2020 Apr 1;77(4):387-396
pubmed: 31825511
Eur Arch Psychiatry Clin Neurosci. 2021 Feb;271(1):135-156
pubmed: 33211157
Psychiatry Res. 2022 Apr;310:114471
pubmed: 35227989
Brain Stimul. 2013 Sep;6(5):831-3
pubmed: 23602026
Schizophr Bull. 2011 Jul;37(4):709-15
pubmed: 21436317
N Engl J Med. 2018 Dec 6;379(23):2237-2245
pubmed: 30575457
East Asian Arch Psychiatry. 2017 Dec;27(4):162-4
pubmed: 29259147
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):702-7
pubmed: 14744917
Schizophr Res. 2010 Aug;121(1-3):1-14
pubmed: 20579855
Vision Res. 2001;41(10-11):1459-74
pubmed: 11322986
Neuroscientist. 2011 Feb;17(1):37-53
pubmed: 21343407
Brain Stimul. 2021 Nov-Dec;14(6):1483-1485
pubmed: 34597856
Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16947-51
pubmed: 15556997
Mov Disord Clin Pract. 2017 Mar 16;4(5):717-723
pubmed: 28435846
BMC Neurol. 2008 Jun 20;8:21
pubmed: 18570642
Neuropsychobiology. 2014;70(1):10-22
pubmed: 25170847
Behav Res Methods. 2020 Apr;52(2):464-488
pubmed: 31152384
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5747-5755
pubmed: 30833389
Psychiatry Res. 2017 Jun;252:154-160
pubmed: 28273630
Schizophr Bull. 2019 Feb 1;45(45 Suppl 1):S67-S77
pubmed: 30715544
Lancet Psychiatry. 2020 Jan;7(1):64-77
pubmed: 31860457
Psychol Med. 2019 Jul;49(10):1740-1748
pubmed: 30178729